Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Tirzepatide (GLP-2) research overview

Tirzepatide, originally identified as LY3298176, is a single peptide studied as an agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). The catalog shorthand “GLP-2” does not refer to the separate endogenous GLP-2 hormone or its receptor.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Tirzepatide (GLP-2)?

The discovery program combined biochemical assays, cell systems, animal models, and early human work. Later receptor studies described asymmetric signaling at GIPR and GLP-1R. Those findings characterize the investigators' material, not an independently supplied research batch.

Research category
Metabolic & energy research
Study models represented
Receptor assays, cells, rodents, phase 1 and phase 2 studies
Names in the literature
Tirzepatide; LY3298176; GIPR/GLP-1R dual agonist
Primary boundary
Clinical-trial material and outcomes are not transferable to separately sourced research material.

What does the selected evidence support?

A phase 2 randomized trial studied a characterized clinical formulation in adults with type 2 diabetes. Results from that protocol cannot establish interchangeability, safety, or efficacy for a research-use-only catalog material.

Primary sources

  1. Coskun et al., Molecular Metabolism (2018) — Discovery and translational studies of the dual GIP/GLP-1 receptor agonist LY3298176. DOI: 10.1016/j.molmet.2018.09.009
  2. Frias et al., The Lancet (2018) — Randomized phase 2 study in adults with type 2 diabetes. DOI: 10.1016/S0140-6736(18)32260-8
  3. Willard et al., JCI Insight (2020) — Receptor pharmacology describing imbalanced and biased dual agonism. DOI: 10.1172/jci.insight.140532

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Tirzepatide (GLP-2) product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.